1
Return

Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy

delete2026-07-29
delete0
delete
OA
AI
A
Anne-Laure Mallard de La Varende
A
Ai-Ling Tian
S
Simon Thomas
I
Imran Lahmar
M
Meriem Messaoudene
S
Sijing Li
O
Omar Motiño
H
Hortense Guillaume-dit-Taunière
V
Valerio Iebba
Y
Yoan Hurtado
T
Thao-Nguyen Pham
C
Cassandra Thélémaque
M
Miguel Araujo‐Voces
D
Déborah Suissa
P
Pierre Ly
E
Ella Reich
G
Giacomo Vitali
B
Bryan Thierry Arlunno
S
Sylvère Durand
F
Fanny Aprahamian
DOI：10.1016/j.ccell.2026.06.022delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
• Gut dysbiosis reshapes bile acids and weakens cancer immunotherapy • Metabolic or microbiota interventions compensate dysbiosis-related bile acid shifts • Glycodeoxycholic acid compensates ileal MAdCAM-1 loss and TIL exhaustion • Subclinical cholestasis predicted primary resistance to cancer immunotherapy
Keywords:
cancer
PD-1
immune checkpoint blockade
bile acids
mucosal addressin cell adhesion molecule 1
MAdCAM-1
antibiotics
gut microbiota
microbiome
immunotherapy

Journal

Cancer Cell cover
Cancer Cell
IF:
44.5
Papers:
413
Citations:
5.6W

Organization

No organization information available
Cited Papers

Cited Papers

Citing Papers

Citing Papers